Baptist Memorial Hospital-Jonesboro INC
Baptist Memorial Hospital-Jonesboro INC was paid $17.05M by Medicaid between Jan 2018 and Dec 2024, across 276 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 6.9% of everything it billed.
JONESBORO, AR 72401
Next to other Multi-Specialty Clinic/Center providers in Arkansas
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 85,546 | $1.30M | |
| 2019 | 129,960 | $2.17M | |
| 2020 | 92,228 | $1.94M | |
| 2021 | 122,011 | $2.67M | |
| 2022 | 135,083 | $3.22M | |
| 2023 | 145,972 | $3.24M | |
| 2024incomplete | 118,617 | $2.51M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 6.9% | 55,243 | 40,033 | $1.18M |
| 70450 | Computed tomography, head or brain; without contrast material | 6.2% | 9,807 | 8,334 | $1.05M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.6% | 6,622 | 5,666 | $953K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 3.8% | 14,439 | 12,536 | $649K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 3.6% | 2,288 | 1,875 | $606K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 3.5% | 2,578 | 2,169 | $594K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.9% | 43,878 | 20,058 | $488K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.8% | 7,237 | 4,825 | $475K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.6% | 4,696 | 3,775 | $438K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.5% | 59,339 | 41,383 | $430K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.2% | 4,759 | 4,050 | $368K |
| 72125 | Computed tomography, cervical spine; without contrast material | 2.0% | 2,884 | 2,456 | $343K |
264 more codes
| 72141 | 1.8% | 1,474 | $300K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 1.7% | 1,066 | $286K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.6% | 14,529 | $278K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.6% | 2,087 | $275K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.4% | 5,086 | $244K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.4% | 1,665 | $238K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.4% | 3,629 | $237K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.4% | 24,993 | $237K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.3% | 1,275 | $226K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 6,840 | $226K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 1.3% | 742 | $218K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1.2% | 12,213 | $209K |
| 99283 | Emergency room visit (moderate) | 1.1% | 4,832 | $185K |
| 70486 | 1.0% | 1,414 | $178K | |
| 42830 | 1.0% | 623 | $176K | |
| 71045 | Radiologic examination, chest; single view | 1.0% | 19,854 | $176K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 10,056 | $172K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,305 | $155K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 4,613 | $143K |
| 84484 | <1% | 18,090 | $133K | |
| 85027 | <1% | 15,732 | $132K | |
| 81001 | <1% | 33,980 | $132K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,469 | $130K |
| 99284 | Emergency room visit (serious) | <1% | 4,846 | $126K |
| 83880 | <1% | 5,840 | $122K | |
| 62323 | <1% | 785 | $118K | |
| 83735 | <1% | 20,270 | $116K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,675 | $115K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 9,636 | $108K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 15,951 | $107K |
| 71250 | <1% | 1,559 | $106K | |
| 87807 | <1% | 9,142 | $105K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,350 | $102K |
| 81025 | <1% | 10,500 | $99K | |
| 80050 | General health panel | <1% | 1,476 | $98K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,214 | $97K |
| 72158 | <1% | 438 | $95K | |
| 73560 | <1% | 2,978 | $85K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,371 | $83K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,085 | $79K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,733 | $77K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,734 | $77K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,363 | $76K |
| 99285 | Emergency room visit (most serious) | <1% | 3,760 | $73K |
| 72131 | <1% | 645 | $71K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 4,168 | $68K |
| 86901 | <1% | 3,133 | $64K | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 8,627 | $64K |
| 84703 | <1% | 6,062 | $62K | |
| 83690 | <1% | 8,790 | $60K | |
| 87040 | <1% | 6,065 | $59K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,416 | $58K |
| 73630 | <1% | 2,114 | $56K | |
| 73221 | <1% | 248 | $55K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,683 | $55K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 254 | $52K |
| 74018 | <1% | 2,836 | $51K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,001 | $50K |
| 93017 | <1% | 2,343 | $48K | |
| 83605 | <1% | 5,192 | $48K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,644 | $48K |
| 94760 | <1% | 4,765 | $46K | |
| 76642 | <1% | 1,685 | $45K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,433 | $44K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,806 | $44K |
| 93971 | <1% | 1,183 | $44K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 216 | $44K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,123 | $43K |
| 73030 | <1% | 1,836 | $40K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 200 | $39K |
| 77066 | Tomosynthesis, mammo | <1% | 586 | $39K |
| 73610 | <1% | 2,077 | $38K | |
| 85610 | <1% | 5,988 | $36K | |
| 73130 | <1% | 1,518 | $35K | |
| 82565 | <1% | 2,200 | $35K | |
| 74022 | <1% | 1,238 | $35K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,052 | $35K |
| 73502 | <1% | 1,160 | $35K | |
| 80061 | Lipid panel | <1% | 2,069 | $34K |
| 84702 | <1% | 3,295 | $34K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,426 | $31K |
| 93458 | <1% | 323 | $31K | |
| 43235 | <1% | 260 | $29K | |
| 86140 | <1% | 5,439 | $28K | |
| 73110 | <1% | 1,294 | $28K | |
| 82803 | <1% | 1,832 | $27K | |
| 82728 | <1% | 2,234 | $27K | |
| 72100 | <1% | 1,168 | $26K | |
| 85379 | <1% | 2,931 | $26K | |
| 93880 | <1% | 941 | $25K | |
| 85730 | <1% | 4,335 | $23K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 374 | $23K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,381 | $23K |
| 84439 | <1% | 737 | $21K | |
| 84145 | <1% | 1,353 | $21K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,511 | $20K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 15,886 | $20K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,265 | $19K |
| 82375 | <1% | 1,822 | $17K | |
| 64493 | <1% | 94 | $16K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 75 | $16K |
| 85007 | <1% | 4,006 | $15K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,778 | $15K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 548 | $14K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,107 | $14K |
| G0378 | Hospital observation service, per hour | <1% | 2,281 | $13K |
| 70491 | <1% | 83 | $13K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 249 | $13K |
| J2704 | Injection, propofol, 10 mg | <1% | 7,549 | $13K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,228 | $12K |
| 86850 | <1% | 2,210 | $11K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 848 | $10K |
| 86900 | <1% | 2,764 | $10K | |
| 87210 | <1% | 1,975 | $10K | |
| 77336 | <1% | 283 | $10K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 230 | $10K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,315 | $10K |
| 97161 | <1% | 494 | $9K | |
| 97162 | <1% | 186 | $8K | |
| 97166 | <1% | 223 | $8K | |
| 76830 | Ultrasound, transvaginal | <1% | 134 | $8K |
| 81003 | <1% | 1,326 | $8K | |
| 90715 | <1% | 540 | $8K | |
| 83050 | <1% | 1,828 | $8K | |
| 83615 | <1% | 1,579 | $7K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 128 | $7K |
| 76536 | <1% | 213 | $7K | |
| 76801 | <1% | 215 | $7K | |
| 73590 | <1% | 261 | $6K | |
| 12001 | <1% | 41 | $6K | |
| 74178 | <1% | 80 | $6K | |
| 83550 | <1% | 954 | $6K | |
| 83655 | <1% | 341 | $6K | |
| 83540 | <1% | 1,101 | $6K | |
| 82150 | <1% | 890 | $6K | |
| 84550 | <1% | 1,451 | $6K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 35 | $5K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,734 | $5K |
| 96367 | <1% | 239 | $5K | |
| 85652 | <1% | 2,148 | $5K | |
| 77062 | <1% | 62 | $5K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 135 | $5K |
| 76770 | <1% | 188 | $5K | |
| 77080 | <1% | 131 | $5K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 137 | $5K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,274 | $5K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,503 | $4K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,137 | $4K |
| 82550 | <1% | 712 | $4K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 674 | $4K |
| 12011 | <1% | 43 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 648 | $4K |
| 86308 | <1% | 703 | $4K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 327 | $4K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 60 | $4K |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 150 | $4K |
| 93922 | <1% | 212 | $4K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 40 | $4K |
| 73090 | <1% | 176 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 7,003 | $3K |
| 87070 | <1% | 256 | $3K | |
| 82607 | <1% | 304 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,893 | $3K |
| 36591 | <1% | 134 | $3K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,014 | $3K |
| 80320 | <1% | 206 | $3K | |
| 70496 | <1% | 13 | $3K | |
| 73080 | <1% | 125 | $3K | |
| 29125 | <1% | 12 | $3K | |
| 29515 | <1% | 12 | $3K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 21 | $2K |
| 93970 | <1% | 114 | $2K | |
| 64483 | <1% | 13 | $2K | |
| 84100 | <1% | 499 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,175 | $2K |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,193 | $2K |
| 73140 | <1% | 97 | $2K | |
| 80329 | <1% | 107 | $2K | |
| 85045 | <1% | 479 | $1K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 105 | $1K |
| 87205 | <1% | 358 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,260 | $1K |
| 77065 | Tomosynthesis, mammo | <1% | 59 | $1K |
| 82746 | <1% | 150 | $1K | |
| 92508 | Group treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 77 | $1K |
| 71271 | <1% | 32 | $1K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 2,590 | $1K |
| 82270 | <1% | 409 | $1K | |
| 73521 | <1% | 74 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,480 | $1K |
| 82009 | <1% | 276 | $1K | |
| 96376 | <1% | 540 | $991.56 | |
| 70498 | <1% | 20 | $950.44 | |
| 76870 | <1% | 28 | $918.78 | |
| C1769 | Guide wire | <1% | 59 | $821.63 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 540 | $815.14 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 952 | $779.02 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 44 | $764.21 |
| 77085 | <1% | 43 | $652.13 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 894 | $645.41 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 276 | $638.02 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 478 | $600.99 |
| 93320 | <1% | 16 | $588.36 | |
| 71101 | <1% | 15 | $586.51 | |
| A9609 | Fludeoxyglucose f18 up to 15 millicuries | <1% | 17 | $573.62 |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 80 | $538.89 |
| 97602 | <1% | 22 | $535.99 | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 15 | $525.05 |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 101 | $517.32 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,776 | $486.99 |
| 90686 | <1% | 125 | $465.44 | |
| 73070 | <1% | 29 | $369.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 369 | $296.02 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 266 | $290.48 |
| 72170 | <1% | 17 | $274.21 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 3,099 | $263.83 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 286 | $253.04 |
| A9270 | Non-covered item or service | <1% | 7,279 | $235.54 |
| 96415 | <1% | 159 | $232.88 | |
| 77427 | <1% | 72 | $217.69 | |
| 84156 | <1% | 50 | $207.38 | |
| 82570 | <1% | 32 | $206.44 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 162 | $193.92 |
| 80076 | <1% | 30 | $186.72 | |
| 84165 | <1% | 30 | $167.35 | |
| 73552 | <1% | 13 | $165.16 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 85 | $153.05 |
| 88342 | <1% | 38 | $151.59 | |
| 84132 | <1% | 43 | $147.10 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 67 | $141.80 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 299 | $139.68 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 507 | $138.05 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 76 | $123.46 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 15 | $120.35 |
| 36600 | <1% | 1,098 | $115.86 | |
| G0008 | Administration of influenza virus vaccine | <1% | 71 | $112.32 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 769 | $111.45 |
| 82248 | <1% | 15 | $100.38 | |
| 82140 | <1% | 12 | $78.31 | |
| 82947 | <1% | 17 | $76.66 | |
| J2305 | Injection, nitroglycerin, 5 mg | <1% | 53 | $62.40 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 100 | $59.32 |
| 85014 | <1% | 28 | $50.70 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 916 | $40.96 |
| 97116 | <1% | 1,755 | $28.74 | |
| 96417 | <1% | 229 | $18.09 | |
| 92610 | <1% | 46 | $12.67 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 4,282 | $11.89 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 53 | $8.00 |
| J0595 | Injection, butorphanol tartrate, 1 mg | <1% | 94 | $7.88 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 45 | $5.40 |
| J1815 | Injection, insulin, per 5 units | <1% | 22 | $0.29 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 236 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 36 | $0.00 |
| J3490 | Unclassified drugs | 0% | 22 | $0.00 |
| 94762 | 0% | 22 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 15 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 451 | $0.00 |
| J0736 | Injection, clindamycin phosphate, 300 mg | 0% | 28 | $0.00 |
| 93356 | 0% | 21 | $0.00 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 0% | 18 | $0.00 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 25 | $0.00 |
| 76942 | 0% | 29 | $0.00 | |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | 0% | 23 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.